You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

MANNITOL 20% Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Mannitol 20%, and what generic alternatives are available?

Mannitol 20% is a drug marketed by B Braun, Hospira, Miles, and Icu Medical Inc. and is included in six NDAs.

The generic ingredient in MANNITOL 20% is mannitol. There are eighteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the mannitol profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MANNITOL 20%?
  • What are the global sales for MANNITOL 20%?
  • What is Average Wholesale Price for MANNITOL 20%?
Summary for MANNITOL 20%
Drug patent expirations by year for MANNITOL 20%
Recent Clinical Trials for MANNITOL 20%

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Hospital, GenevaPhase 3
Morten Hostrup, PhDN/A
Ecole Polytechnique Fédérale de LausanneEarly Phase 1

See all MANNITOL 20% clinical trials

Pharmacology for MANNITOL 20%
Drug ClassOsmotic Diuretic
Mechanism of ActionOsmotic Activity
Physiological EffectIncreased Diuresis

US Patents and Regulatory Information for MANNITOL 20%

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
B Braun MANNITOL 20% mannitol INJECTABLE;INJECTION 014738-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Miles MANNITOL 20% mannitol INJECTABLE;INJECTION 016472-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
B Braun MANNITOL 20% mannitol INJECTABLE;INJECTION 016080-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for MANNITOL 20%

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pharmaxis Europe Limited Bronchitol mannitol EMEA/H/C/001252
Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.
Authorised no no no 2012-04-13
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.